| Be it enacted by the People of the State of Maine as follows: |
|
| | Sec. 1. 22 MRSA c. 605 is enacted to read: |
|
| PRESCRIPTION DRUG ADVERTISING |
|
| §2700-A.__Prohibitions and required disclosures |
|
| | 1.__Definitions.__As used in this chapter, unless the context | otherwise indicates, "clinical trial" means a clinical | investigation as defined by the federal Food and Drug | Administration that involves any experiment to test the safety or | efficacy of a drug or biological product with one or more human | subjects and is intended to be submitted to, or held for | inspection by, the federal Food and Drug Administration as part | of an application for a research or marketing permit. |
|
| | 2. Adoption of federal law and regulations by reference.__The | department shall adopt rules to incorporate by reference federal | statutes and regulations in 21 United States Code, Sections 331 | and 352(n) and 21 Code of Federal Regulations, Part 202 and may | adopt amendments to those statutes and regulations that are not | inconsistent with those statutes and regulations.__Rules adopted | pursuant to this subsection are routine technical rules as | defined in Title 5, chapter 375, subchapter 2-A. |
|
| | 3. Misbranding and certain advertising prohibited.__A | manufacturer may not present or cause to be presented an | advertisement for a prescription drug in a television broadcast, | radio broadcast or printed material that originates in this | State, unless that advertisement meets the requirements of | federal laws and regulations concerning misbranded drugs and | devices and prescription drug advertising as adopted by reference | by rule of the department pursuant to subsection 2. |
|
| | 4.__Disclosure of clinical trials. A manufacturer may not | present or cause to be presented an advertisement for a | prescription drug in a television broadcast, radio broadcast or | printed material that originates in this State, unless the | manufacturer has disclosed to the department, on a form provided | by the department, the following information concerning any | clinical trial of the prescription drug that the manufacturer has | conducted or sponsored or is in the process of conducting or | sponsoring: |
|
| A. The name of the entity that conducted or is conducting | the clinical trial; |
|
|